Appili Therapeutics Inc (APLI) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.018x

Based on the latest financial reports, Appili Therapeutics Inc (APLI) has a cash flow conversion efficiency ratio of 0.018x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-293.07K ≈ $-212.00K USD) by net assets (CA$-16.38 Million ≈ $-11.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Appili Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Appili Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Appili Therapeutics Inc (APLI) financial obligations for a breakdown of total debt and financial obligations.

Appili Therapeutics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Appili Therapeutics Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
NASDAQ:CUPR
N/A
Mobeus Income And Growth Vct Plc
LSE:MIX
-0.004x
OurLiving AB
ST:OURLIV
-4.139x
Camellia Plc
LSE:CAM
-0.059x
Helios Underwriting PLC
LSE:HUW
-0.486x
Alpha Star Acquisition Corp
NASDAQ:ALSA
0.087x
Gentlemens Equity S.A.
PA:MLGEQ
N/A
Fintech Chain Ltd
AU:FTC
-0.019x

Annual Cash Flow Conversion Efficiency for Appili Therapeutics Inc (2017–2025)

The table below shows the annual cash flow conversion efficiency of Appili Therapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Appili Therapeutics Inc (APLI) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 CA$-13.40 Million
≈ $-9.69 Million
CA$868.82K
≈ $628.49K
-0.065x -128.75%
2024-03-31 CA$-10.92 Million
≈ $-7.90 Million
CA$-2.46 Million
≈ $-1.78 Million
0.226x -83.48%
2023-03-31 CA$-7.40 Million
≈ $-5.35 Million
CA$-10.10 Million
≈ $-7.30 Million
1.365x -76.60%
2022-03-31 CA$-3.27 Million
≈ $-2.37 Million
CA$-19.08 Million
≈ $-13.80 Million
5.834x +749.77%
2021-03-31 CA$12.75 Million
≈ $9.23 Million
CA$-11.45 Million
≈ $-8.28 Million
-0.898x -86.42%
2020-03-31 CA$8.85 Million
≈ $6.40 Million
CA$-4.26 Million
≈ $-3.08 Million
-0.482x +38.42%
2019-03-31 CA$4.42 Million
≈ $3.20 Million
CA$-3.46 Million
≈ $-2.50 Million
-0.782x -15.22%
2018-03-31 CA$4.87 Million
≈ $3.52 Million
CA$-3.30 Million
≈ $-2.39 Million
-0.679x +56.34%
2017-03-31 CA$1.37 Million
≈ $994.41K
CA$-2.14 Million
≈ $-1.55 Million
-1.555x --

About Appili Therapeutics Inc

TO:APLI Canada Biotechnology
Market Cap
$1.86 Million
CA$2.57 Million CAD
Market Cap Rank
#29757 Global
#1511 in Canada
Share Price
CA$0.02
Change (1 day)
+33.33%
52-Week Range
CA$0.01 - CA$0.04
All Time High
CA$1.87
About

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paro… Read more